Manilam Industries IPO made its stock market debut following its subscription phase that concluded earlier…

Gaudium IVF IPO Listing Update: Date, Performance and What to Watch
The Gaudium IVF and Women Health Ltd. IPO is set to make its stock market debut after receiving strong participation during the subscription period. The public issue witnessed an overall subscription of 7.27 times, with bids placed for more than 10.63 crore shares against 1.46 crore shares on offer.

The allotment of shares was finalized on 25 February 2026, while refunds and credit of shares to Demat accounts were processed on 26 February 2026. The IPO is scheduled to list on both the BSE and NSE on 27 February 2026.

Image Reference : https://www.bseindia.com/
Shares of Gaudium IVF and Women Health were listed at Rs 83 per share on the NSE, a premium of 5.06 percent. The Rs 165-crore IPO had a price band of Rs 75-79 per share.

Gaudium IVF IPO Listing Details
| Listing Date | 27 February 2026 |
| Allotment Date | 25 February 2026 |
| Refund Initiation | 26 February 2026 |
| Credit to Demat | 26 February 2026 |
| Issue Type | Book Built Issue |
| Face Value | ₹10 per share |
| Listing price | Rs 83 per share |
Gaudium IVF IPO Subscription Data
| Category | Subscription (Times) |
|---|---|
| QIB | 8.88x |
| NII | 7.32x |
| RII | 4.27x |
| Total | 7.27x |
The IPO saw strong institutional interest, with Qualified Institutional Buyers subscribing 8.88 times their allocated portion. Non-Institutional Investors followed closely at 7.32 times, while Retail Individual Investors subscribed 4.27 times.

Grey Market Premium (GMP) Trend
| Date | IPO GMP | Trend |
|---|---|---|
| 26 February 2026 | ₹-3 | Weak |
| 25 February 2026 | ₹-2 | Soft |
| 24 February 2026 | ₹0 | Flat |
Recent grey market activity indicates a mild discount ahead of listing, suggesting cautious sentiment in the unofficial market. Investors will closely monitor the opening trade on 27 February 2026 to assess how the stock performs compared to its issue price.
Market participants will also watch broader market conditions and healthcare sector sentiment, as these factors could influence the stock’s debut performance.